Wright, Richard F <br/><br/>
Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study.  [electronic resource] 

 -  Journal of clinical hypertension (Greenwich, Conn.)  Aug 2011 
 - 588-97 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1751-7176 
<br/><br/><label>Standard No.: </label>10.1111/j.1751-7176.2011.00492.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amlodipine--adverse effects<br/>Angiotensin Receptor Antagonists--adverse effects<br/>Blood Pressure--drug effects<br/>Calcium Channel Blockers--adverse effects<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Hydrochlorothiazide--adverse effects<br/>Hypertension--drug therapy<br/>Losartan--adverse effects<br/>Male<br/>Middle Aged<br/>Severity of Illness Index<br/>Tetrazoles--adverse effects<br/>Treatment Outcome<br/>United States<br/>Valine--adverse effects<br/>Valsartan